Literature DB >> 21674132

Determinants of intracranial hemorrhage incidence in patients on oral anticoagulation followed at the Lahey clinic.

Simon Mantha1, Ann Marie Pianka, Nicholas Tsapatsaris.   

Abstract

Oral anticoagulation with warfarin is widely used to treat venous and arterial thromboembolic disease (Ansell et al. Chest 133(6 suppl):160S-198S, 2008). Its administration is associated with a risk of intracranial hemorrhage (ICH), a devastating complication which usually results in death or severe disability (Fang et al. Am J Med,120(8):700-705, 2007; Rosand et al. Arch Intern Med, 164(8):880-884, 2004). The international normalized ratio (INR) is one of the factors which can help determine the risk of ICH in a given individual (Singer et al. Circ Cardiovasc Qual Outcomes, 2(4):297-304, 2009). Using the DoseResponse(®) patient database at our institution, we carried a retrospective nested matched case-control study to identify patient characteristics associated with the occurrence of ICH. The database was queried for the years 2004-2009. Each case was matched by month to four control patients having a routine INR determination for the monitoring of chronic anticoagulation. The following characteristics were captured: bleeding type, INR, age, sex, blood pressure, hemoglobin, creatinine, presence or history of pertinent comorbid conditions, intake of antiplatelet agents (aspirin or thienopyridine) and indication for anticoagulation. The relationship between those risk factors and the odds ratio of ICH was determined with conditional logistic regression. Fifty cases of ICH were retrieved. When correcting for pertinent variables, the odds ratio of ICH increased significantly for higher INR values, with a quadratic relationship noted in the model. Increasing mean blood pressure seemed to be associated with a higher risk of ICH, also in an exponential manner. Rising hemoglobin values on the other hand seemed to have a protective effect against such events. About 50% of cases of ICH occurred in or below the therapeutic INR range. The intake of antiplatelet agent was found to be associated with ICH in univariate analysis only. The INR is an important predictor for the incidence of ICH, but in this study an elevated measurement was found in only half of cases. Mean blood pressure appears to be another important determinant of the risk of ICH in the anticoagulated patient population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21674132     DOI: 10.1007/s11239-011-0609-2

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  32 in total

1.  Platelet-induced thrombin generation time II (PITT II). A modified global coagulation test to monitor prophylactic anticoagulation with vitamin K antagonists?

Authors:  P Radziwon; B Boczkowska-Radziwon; J F Schenk; M Z Wojtukiewicz; J Kloczko; J Giedrojć; H K Breddin
Journal:  Thromb Res       Date:  1999-10-01       Impact factor: 3.944

2.  Recollections on thrombin generation.

Authors:  H Coenraad Hemker
Journal:  J Thromb Haemost       Date:  2007-12-10       Impact factor: 5.824

3.  Thrombin generation test in patients under anticoagulant therapy with vitamin K antagonists.

Authors:  Isabel Brocal; Pascual Marco; Javier Lucas; José Verdú; Fabián Tarín
Journal:  Thromb Haemost       Date:  2009-03       Impact factor: 5.249

4.  Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy.

Authors:  C S Landefeld; L Goldman
Journal:  Am J Med       Date:  1989-08       Impact factor: 4.965

5.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).

Authors:  Brian F Gage; Yan Yan; Paul E Milligan; Amy D Waterman; Robert Culverhouse; Michael W Rich; Martha J Radford
Journal:  Am Heart J       Date:  2006-03       Impact factor: 4.749

6.  The generation of thrombin in whole plasma. Biochemical possibilities and physiological realities.

Authors:  H C Hemker; S Béguin
Journal:  Verh K Acad Geneeskd Belg       Date:  1985

7.  A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group.

Authors: 
Journal:  Ann Neurol       Date:  1997-12       Impact factor: 10.422

8.  Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism.

Authors:  P M Kuijer; B A Hutten; M H Prins; H R Büller
Journal:  Arch Intern Med       Date:  1999-03-08

9.  The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism.

Authors:  Philip S Wells; Melissa A Forgie; Maureen Simms; Alison Greene; Donna Touchie; Geoffrey Lewis; Jodi Anderson; Marc A Rodger
Journal:  Arch Intern Med       Date:  2003-04-28

10.  Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin.

Authors:  R J Beyth; L M Quinn; C S Landefeld
Journal:  Am J Med       Date:  1998-08       Impact factor: 4.965

View more
  2 in total

1.  Genetic risk factors for major bleeding in patients treated with warfarin in a community setting.

Authors:  J A Roth; D Boudreau; M M Fujii; F M Farin; A E Rettie; K E Thummel; D L Veenstra
Journal:  Clin Pharmacol Ther       Date:  2014-02-06       Impact factor: 6.875

2.  Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients.

Authors:  Romain Chopard; Gregory Piazza; Shelley Hurwitz; John Fanikos; Samuel Z Goldhaber
Journal:  J Thromb Thrombolysis       Date:  2019-02       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.